DDInter38 DDInter704
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Aldesleukin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cinoxacin
Cinoxacin {u} (Compound) causes {v} (Side Effect) Somnolence
Somnolence {u} (Side Effect) is caused by {v} (Compound) Everolimus
Aldesleukin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ofloxacin
Ofloxacin {u} (Compound) downregulates {v} (Gene) PTPN1
PTPN1 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Aldesleukin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Norfloxacin
Norfloxacin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Aldesleukin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Norfloxacin
Norfloxacin {u} (Compound) downregulates {v} (Gene) PRR7
PRR7 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Aldesleukin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Sparfloxacin {u} (Compound) upregulates {v} (Gene) KCTD5
KCTD5 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Aldesleukin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Grepafloxacin
Grepafloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Epirubicin {u} (Compound) upregulates {v} (Gene) SCPEP1
SCPEP1 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methyldopa
Methyldopa {u} (Compound) upregulates {v} (Gene) HSD17B10
HSD17B10 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pentostatin
Pentostatin {u} (Compound) causes {v} (Side Effect) Foetor hepaticus
Foetor hepaticus {u} (Side Effect) is caused by {v} (Compound) Everolimus
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tamoxifen
Tamoxifen {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Cinoxacin and Cinoxacin (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Everolimus (Compound)
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Ofloxacin and Ofloxacin (Compound) downregulates PTPN1 (Gene) and PTPN1 (Gene) is upregulated by Everolimus (Compound)
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Norfloxacin and Norfloxacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound)
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Norfloxacin and Norfloxacin (Compound) downregulates PRR7 (Gene) and PRR7 (Gene) is downregulated by Everolimus (Compound)
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin (Compound) upregulates KCTD5 (Gene) and KCTD5 (Gene) is upregulated by Everolimus (Compound)
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin (Compound) upregulates SCPEP1 (Gene) and SCPEP1 (Gene) is upregulated by Everolimus (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Methyldopa and Methyldopa (Compound) upregulates HSD17B10 (Gene) and HSD17B10 (Gene) is downregulated by Everolimus (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Pentostatin and Pentostatin (Compound) causes Foetor hepaticus (Side Effect) and Foetor hepaticus (Side Effect) is caused by Everolimus (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound)